1. Inflammation was long viewed primarily as a protective immune response. What pivotal discoveries have most fundamentally shifted our understanding of inflammation as a driver of chronic and complex diseases?
Inflammation is now recognised as a core biological process that, when dysregulated, contributes to a wide spectrum of chronic and complex diseases, including cardiovascular disease and cancer. Although many discoveries have shaped this shift, few have been particularly influential: evidence that low-grade, persistent inflammation can quietly influence long-term health; recognition that interconnected immune-signaling networks can sustain chronic inflammatory states; and insights showing that the microbiome, metabolism, and environmental exposures continuously modulate how inflammation is triggered and resolved.
Collectively, these advances reframed inflammation from a short-term protective response to a central driver of chronic, multifactorial disease.
2. Immune dysregulation is now central to many pathological conditions. How do disruptions in immune homeostasis differ across cancer, autoimmunity, infectious diseases, and immunodeficiencies - and what does this mean for therapeutic design?
Immune dysregulation underlies many diseases, but its patterns differ across conditions. In cancer, tumours evade surveillance through immune suppression and T-cell exhaustion.
Autoimmune diseases result from loss of self-tolerance and persistent immune activation, causing self-directed inflammation. Infectious diseases can trigger damaging hyperinflammation or exploit immune evasion to weaken defenses. Immunodeficiencies arise from intrinsic defects that prevent effective immune responses. Understanding these distinct mechanisms enables therapies that precisely modulate immune activity to restore balance without compromising host protection.
3. Cellular heterogeneity within immune populations is gaining attention. How has single- cell analysis transformed our ability to map inflammatory microenvironments, and what new therapeutic vulnerabilities has it revealed?
Single-cell analysis has reshaped our understanding of inflammatory microenvironments by uncovering the cellular diversity, spatial organisation, and dynamic states that bulk profiling masks. These technologies reveal that inflammation is driven not by broad immune lineages but by discrete pathogenic cell states such as lipid-laden neutrophils or exhausted T cells that arise in response to local cues. Spatial transcriptomics further show that tissue niches, such as hypoxic zones or fibrotic regions, determine whether the same immune cell acts protectively or pathologically, explaining why systemic immune blockade often yields variable outcomes.
Single-cell information also highlights the active role of stromal, endothelial, and fibroblast populations in orchestrating inflammatory circuits through cytokine production, metabolic signalling, and matrix remodelling. Together, these insights redefine inflammatory sites as complex ecosystems and expose therapeutic vulnerabilities within specific cell states, spatial niches, and stromal-immune interactions.
4. Chronic inflammation often persists despite immune activation. From a mechanistic perspective, what roles do immune exhaustion, tolerance, and maladaptive repair play in sustaining inflammatory disease states?
Chronic inflammation persists not because the immune system stays fully activated, but because it becomes dysregulated. Immune exhaustion allows inflammatory signals to continue even as immune cells lose the ability to clear pathogens, damaged cells, or tumours. Immune tolerance further reinforces this state by suppressing destructive immunity through regulatory cells and cytokines, limiting tissue damage but allowing the underlying trigger to persist. At the same time, maladaptive repair programs driven by persistently activated macrophages and altered extracellular matrix turn healing processes into ongoing sources of inflammation. Together, exhaustion, tolerance, and maladaptive repair create a self-reinforcing loop in which inflammation continues without effective resolution.
5. Immune-metabolic reprogramming is emerging as a key driver of inflammatory persistence. How do metabolic shifts within immune cells influence inflammatory signaling, and how druggable are these metabolic pathways?
Immune-metabolic reprogramming has emerged as a major driver of inflammatory persistence, as metabolic pathways not only provide energy but also actively shape immune cell identity, signalling, and functional fate. Shifts toward glycolysis, mitochondrial dysfunction, and altered lipid handling turn immune cells into self-reinforcing inflammatory states while metabolites such as succinate and itaconate act as direct signalling molecules that modulate inflammatory pathways. These reprogrammings are often imposed by tissue niches such as hypoxic microenvironments, creating context-specific metabolic dependencies. Although many metabolic enzymes and transporters are potentially druggable, their widespread tissue expression makes systemic inhibition risky. Shifting therapeutic interest toward niche-restricted vulnerabilities and strategies that reprogram immune metabolism offers new avenues for controlling chronic inflammation.
6. Many inflammatory pathways overlap across seemingly unrelated diseases. How realistic is the development of cross-indication therapies targeting shared inflammatory mechanisms without compromising immune defense?
Cross-indication anti-inflammatory therapies are feasible because many chronic diseases share inflammatory pathways, such as NLRP3 inflammasomes and metabolic stress signaling.
However, their success relies on precise targeting to address disease-driving pathways without impairing essential immunity. The main takeaway: improved precision tools and biomarkers are making such therapies more viable and safer.
7. Precision-guided therapies are reshaping treatment paradigms. How can biomarkers, immune profiling, and systems biology be integrated to stratify patients and predict inflammatory disease trajectories more accurately?
Precision-guided therapy in inflammatory disease requires moving from symptom-based diagnosis to mechanism-driven stratification. This can be achieved by integrating biomarkers, immune profiling, and systems biology into a predictive framework. Biomarkers such as cytokines, metabolites, and mediators reveal disease activity and treatment response. High- dimensional immune profiling, using approaches such as single-cell RNA sequencing, multiplex imaging, and spatial omics, identifies pathogenic cell states and maps immune cell interactions. Systems biology then combines these multi-omics and clinical data into network models that can forecast disease trajectories. Together, these approaches can transform inflammatory disease into a predictive, mechanism-based process, enabling precise patient stratification and trajectory prediction.
8. In oncology, inflammation can both promote and suppress tumour growth. How are next- generation immunotherapies navigating this duality to enhance efficacy while minimising inflammatory toxicity?
Next-generation immunotherapies aim to balance the dual role of inflammation in cancer by amplifying tumour-clearing responses while avoiding those that cause immune escape or toxicity. This can be achieved through several strategies, including tumour-selective activation with conditional checkpoint inhibitors, reprogramming tumour-associated myeloid cells through metabolic and epigenetic modulation, and designing self-regulating cell therapies such as CAR-T with safety switches. These innovations mark a shift from broad immune activation to context- aware immune engineering, harnessing inflammation as a therapeutic tool without collateral damage.
9. Autoimmune and inflammatory disorders often show heterogeneous treatment responses. What lessons have we learned about patient variability, and how should this influence the design of future clinical trials?
Treatment responses in autoimmune and inflammatory diseases vary widely, and this variability is not random; it reflects underlying biology. Patients with the same diagnosis often have different dominant drivers, such as cytokine or metabolic stress, making clinical labels poor predictors of response. Advanced immune profiling shows that activation states and tissue context matter more than simple cell counts. Disease stage also plays a role; for instance, early cytokine-driven phases respond better than late fibrotic stages. Genetics, microbiomes, and prior treatments add further complexity. To address this, future trials must move beyond averaging outcomes and use immune and tissue profiling, adaptive designs, and biomarker-guided stratification. This approach can turn variability from a source of failure into a foundation for precision immunology.
10. Targeting upstream inflammatory mediators offers a broad impact but a higher risk. How do you balance therapeutic breadth versus specificity when developing interventions against inflammatory signalling hubs?
Balancing broad impact with safety when targeting upstream inflammatory hubs requires precision rather than absolute inhibition. The key is to identify patients whose disease is genuinely driven by these pathways using biomarkers such as cytokine profiles, signalling states, and immune phenotypes, so treatment is focused where it matters most. Limiting exposure by where and when the drug acts is equally important: tissue-targeted delivery, cell-specific approaches, and short dosing windows can reduce systemic risk. Current strategies emphasise modulation instead of full inhibition, adjusting signalling toward resolution and targeting only pathogenic interactions. This approach preserves normal immune function while curbing pathological inflammation.
11. Emerging modalities such as RNA therapeutics, cell-based therapies, and engineered antibodies are entering the inflammation space. Which of these platforms holds the greatest promise for durable inflammatory control, and why?
RNA therapeutics, engineered antibodies, and cell-based therapies are all advancing in the inflammation space, each with distinct strengths. Engineered antibodies are highly specific, making them suitable for chronic conditions having a defined target. RNA therapeutics enable modulation of intracellular targets that were previously inaccessible. Cell-based therapies have the potential to restore immune balance, though they involve greater complexity and risk.
Ultimately, the choice of platform will depend on disease biology, treatment goals, and the balance between efficacy, durability, and risk.
12. Chronic inflammation is increasingly linked to aging and metabolic disease. How do you see the convergence of immunology, metabolism, and geroscience shaping next-generation therapeutic strategies?
Chronic inflammation link between ageing and metabolic disease is driving a shift in therapeutic strategies toward restoring immune-metabolic balance rather than simply suppressing inflammation. Immune cell behaviour is strongly influenced by metabolism: pro-inflammatory cells rely on glycolysis, while regulatory cells favour oxidative phosphorylation. This opens new therapeutic options, such as drugs that reprogram metabolism, improve mitochondrial health, or target nutrient-sensing pathways. Ageing adds another layer of complexity through persistent low-grade inflammation driven by senescent cells, mitochondrial dysfunction, and tissue barrier breakdown. Future therapies will aim to lower the chronic inflammatory baseline and promote resolution, offering a more holistic approach to healthy ageing and metabolic resilience.
13. Safety remains a major concern when modulating immune pathways. What innovative approaches are being explored to achieve long-term inflammatory suppression without inducing immunosuppression or infection risk?
Achieving long-term inflammatory control without causing immunosuppression needs targeted approach. Emerging strategies focus on targeting inflammation only where it is harmful. For example, prodrugs can activate locally in inflamed tissue, and bispecific antibodies can block pathogenic signals only in specific cells or tissues. Another approach is engineered regulatory cells, such as Tregs, designed to sense inflammation and release anti-inflammatory mediators locally. Real-time immune monitoring and adaptive systems can further guide when and how therapy is applied. The future of safety lies in smart, context-specific modulation, teaching the immune system to resolve inflammation instead of simply shutting it down.
14. Looking ahead, what do you believe will define the next breakthrough in inflammation research - and how close are we to translating these insights into transformative, real-world therapies?
The next big step in inflammation research will be to precisely reprogram immune and metabolic systems. More evidence shows that chronic inflammation is tied to defects in immune cell metabolism, making metabolic checkpoints good targets to reset immune activity and prevent diseases like cancer. At the same time, detailed high-resolution mapping of cell and tissue signals will help us tell harmful from helpful inflammation. New treatments, such as advanced antibodies and adaptive cell therapies, are going to offer flexible, dynamic, feedback-controlled ways to modulate inflammation. Now, AI tools are also helping in combining complex health data to design personalised therapies and shift healthcare from treating illness to preventing it.
